{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:03:24Z","timestamp":1773695004926,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12872-018-0800-x","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T20:36:26Z","timestamp":1528144586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies"],"prefix":"10.1186","volume":"18","author":[{"name":"on behalf of the SMILE Working Project","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7124-2096","authenticated-orcid":false,"given":"Stefano","family":"Omboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Reggiardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Bacchelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela Degli","family":"Esposti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Ambrosioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"issue":"16","key":"800_CR1","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1161\/01.CIR.97.16.1536","volume":"97","author":"Z Mallat","year":"1998","unstructured":"Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 1998;97(16):1536\u20139.","journal-title":"Circulation"},{"issue":"2","key":"800_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3325\/cmj.2012.53.162","volume":"53","author":"V Trkulja","year":"2012","unstructured":"Trkulja V, Car S. On-admission serum uric acid predicts outcomes after acute myocardial infarction: systematic review and meta-analysis of prognostic studies. Croat Med J. 2012;53(2):162\u201372.","journal-title":"Croat Med J"},{"issue":"17","key":"800_CR3","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"800_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.mehy.2007.06.018","volume":"70","author":"X Duan","year":"2008","unstructured":"Duan X, Ling F. Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? Med Hypotheses. 2008;70(3):578\u201381.","journal-title":"Med Hypotheses"},{"issue":"15","key":"800_CR5","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","volume":"107","author":"SD Anker","year":"2003","unstructured":"Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107(15):1991\u20137.","journal-title":"Circulation"},{"issue":"3","key":"800_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/hrt.2006.090845","volume":"93","author":"MM Kittleson","year":"2007","unstructured":"Kittleson MM, St John ME, Bead V, Champion HC, Kasper EK, Russell SD, Wittstein IS, Hare JM. Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart. 2007;93(3):365\u20137.","journal-title":"Heart"},{"issue":"2","key":"800_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1161\/01.CIR.0000022140.61460.1D","volume":"106","author":"CA Farquharson","year":"2002","unstructured":"Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106(2):221\u20136.","journal-title":"Circulation"},{"issue":"7","key":"800_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.cardfail.2006.05.005","volume":"12","author":"HE Cingolani","year":"2006","unstructured":"Cingolani HE, Plastino JA, Escudero EM, Mangal B, Brown J, Perez NG. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata study. J Card Fail. 2006;12(7):491\u20138.","journal-title":"J Card Fail"},{"issue":"6","key":"800_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.cjca.2012.04.005","volume":"28","author":"D Erdogan","year":"2012","unstructured":"Erdogan D, Tayyar S, Uysal BA, Icli A, Karabacak M, Ozaydin M, Dogan A. Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated cardiomyopathy. Can J Cardiol. 2012;28(6):721\u20137.","journal-title":"Can J Cardiol"},{"issue":"20","key":"800_CR10","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","volume":"131","author":"MM Givertz","year":"2015","unstructured":"Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF, Network NHFCR. Effects of xanthine oxidase inhibition in Hyperuricemic heart failure patients: the xanthine oxidase inhibition for Hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015;131(20):1763\u201371.","journal-title":"Circulation"},{"key":"800_CR11","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","volume":"375","author":"A Noman","year":"2010","unstructured":"Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375:2161\u20137.","journal-title":"Lancet"},{"key":"800_CR12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2011.09.072","volume":"59","author":"LH Opie","year":"2012","unstructured":"Opie LH. Allopurinol for heart failure: novel mechanisms. J Am Coll Cardiol. 2012;59:809\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"800_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/147323000503300103","volume":"33","author":"S Evangelista","year":"2005","unstructured":"Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res. 2005;33(1):42\u201354.","journal-title":"J Int Med Res"},{"issue":"4","key":"800_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.amjhyper.2006.09.020","volume":"20","author":"AF Pasini","year":"2007","unstructured":"Pasini AF, Garbin U, Nava MC, Stranieri C, Pellegrini M, Boccioletti V, Luchetta ML, Fabrizzi P, Lo Cascio V, Cominacini L. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens. 2007;20(4):443\u201350.","journal-title":"Am J Hypertens"},{"issue":"2","key":"800_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1056\/NEJM199501123320203","volume":"332","author":"E Ambrosioni","year":"1995","unstructured":"Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The survival of myocardial infarction long-term evaluation (SMILE) study investigators. N Engl J Med. 1995;332(2):80\u20135.","journal-title":"N Engl J Med"},{"issue":"7","key":"800_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/clc.22017","volume":"35","author":"C Borghi","year":"2012","unstructured":"Borghi C, Ambrosioni E, Novo S, Vinereanu D, Ambrosio G, Party S-W. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol. 2012;35(7):416\u201323.","journal-title":"Clin Cardiol"},{"issue":"1","key":"800_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1067\/mhj.2003.24","volume":"145","author":"C Borghi","year":"2003","unstructured":"Borghi C, Ambrosioni E. Survival of myocardial infarction long-term Evaluation-2 working P. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the survival of myocardial infarction long-term Evaluation-2 (SMILE-2) study. Am Heart J. 2003;145(1):80\u20137.","journal-title":"Am Heart J"},{"issue":"3","key":"800_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ahj.2006.12.005","volume":"153","author":"C Borghi","year":"2007","unstructured":"Borghi C, Ambrosioni E, Survival of Myocardial Infarction Long-term Evaluation Study G. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J. 2007;153(3):445. e7\u201314","journal-title":"Am Heart J"},{"key":"800_CR19","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.105.594952","volume":"115","author":"RB D\u2019Agostino","year":"2007","unstructured":"D\u2019Agostino RB. Propensity scores in cardiovascular research. Circulation. 2007;115:2340\u20133.","journal-title":"Circulation"},{"key":"800_CR20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/sim.5991","volume":"33","author":"EJ Williamson","year":"2013","unstructured":"Williamson EJ, Forbes A, White IR. Variance reduction in randomized trials by inverse probability weighting using the propensity score. Statist Med. 2013;33:721\u201337.","journal-title":"Statist Med"},{"key":"800_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2307\/2528036","volume":"24","author":"WG Cochran","year":"1968","unstructured":"Cochran WG. The effectiveness of adjustment by sub-classification in removing bias in observational studies. Biometrics. 1968;24:295\u2013313.","journal-title":"Biometrics"},{"key":"800_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosembaum","year":"1984","unstructured":"Rosembaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516\u201324.","journal-title":"J Am Stat Assoc"},{"issue":"7","key":"800_CR23","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/ard.2007.076232","volume":"67","author":"L Annemans","year":"2008","unstructured":"Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67(7):960\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"800_CR24","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1002\/art.22014","volume":"54","author":"E Krishnan","year":"2006","unstructured":"Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688\u201396.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"800_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134088","volume":"10","author":"SC Liu","year":"2015","unstructured":"Liu SC, Xia L, Zhang J, Lu XH, Hu DK, Zhang HT, Li HJ. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS One. 2015;10(7):e0134088.","journal-title":"PLoS One"},{"issue":"1","key":"800_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2014-000220","volume":"2","author":"C Borghi","year":"2015","unstructured":"Borghi C, Omboni S, Reggiardo G, Bacchelli S, Degli Esposti D, Ambrosioni E. Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. Open Heart. 2015;2(1):e000220.","journal-title":"Open Heart"},{"issue":"2","key":"800_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-2125.2007.02991.x","volume":"65","author":"ML Hansen","year":"2008","unstructured":"Hansen ML, Gislason GH, Kober L, Schramm TK, Folke F, Buch P, Abildstrom SZ, Madsen M, Rasmussen S, Torp-Pedersen C. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol. 2008;65(2):217\u201323.","journal-title":"Br J Clin Pharmacol"},{"key":"800_CR28","doi-asserted-by":"crossref","unstructured":"de Nigris F, D'Armiento FP, Somma P, Casini A, Andreini I, Sarlo F, Mansueto G, De Rosa G, Bonaduce D, Condorelli M, Napoli C. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol. 2001;81(2\u20133):107\u2013115; discusssion 15\u20136.","DOI":"10.1016\/S0167-5273(01)00542-3"},{"issue":"3","key":"800_CR29","first-page":"326","volume":"36","author":"B Altunoluk","year":"2006","unstructured":"Altunoluk B, Soylemez H, Oguz F, Turkmen E, Fadillioglu E. An angiotensin-converting enzyme inhibitor, zofenopril, prevents renal ischemia\/reperfusion injury in rats. Ann Clin Lab Sci. 2006;36(3):326\u201332.","journal-title":"Ann Clin Lab Sci"},{"key":"800_CR30","doi-asserted-by":"crossref","unstructured":"Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, Liguori A. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004;148(1):e5.","DOI":"10.1016\/j.ahj.2004.03.025"},{"issue":"6","key":"800_CR31","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.ahj.2008.09.006","volume":"156","author":"C Napoli","year":"2008","unstructured":"Napoli C, Bruzzese G, Ignarro LJ, Crimi E, de Nigris F, Williams-Ignarro S, Libardi S, Sommese L, Fiorito C, Mancini FP, Cacciatore F, Liguori A. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide\/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J. 2008;156(6):1154. e1\u20138","journal-title":"Am Heart J"},{"issue":"24","key":"800_CR32","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","volume":"51","author":"JM Hare","year":"2008","unstructured":"Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP, Investigators O-C. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51(24):2301\u20139.","journal-title":"J Am Coll Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-018-0800-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-018-0800-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-018-0800-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T19:04:58Z","timestamp":1559675098000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-018-0800-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1186\/s12872-018-0800-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]},"assertion":[{"value":"2 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval of the study protocols was obtained from Ethics Committees of the Coordinating Center at the S. Orsola Hospital in Bologna, Italy and at each participating center. Written informed consent was obtained from each patient before enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Competing interest of Prof Claudio Borghi: consultancy for Boheringer Ingelheim, Menarini International, Sanofi, Amgen, Takeda, Novartis, Ely Lilly and Servier. None of the other authors has any conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"112"}}